A detailed history of Price T Rowe Associates Inc transactions in Ardelyx, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 3,913,863 shares of ARDX stock, worth $29 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,913,863
Previous 2,329,266 68.03%
Holding current value
$29 Million
Previous $14.4 Million 97.84%
% of portfolio
0.0%
Previous 0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$6.05 - $9.74 $9.59 Million - $15.4 Million
1,584,597 Added 68.03%
3,913,863 $28.6 Million
Q4 2023

Feb 14, 2024

BUY
$3.29 - $6.64 $1.96 Million - $3.96 Million
597,099 Added 34.47%
2,329,266 $14.4 Million
Q3 2023

Nov 14, 2023

SELL
$3.3 - $4.83 $136,603 - $199,937
-41,395 Reduced 2.33%
1,732,167 $7.07 Million
Q2 2023

Aug 14, 2023

SELL
$3.23 - $4.95 $2.55 Million - $3.9 Million
-788,234 Reduced 30.77%
1,773,562 $6.01 Million
Q1 2023

May 15, 2023

BUY
$2.68 - $4.79 $711,191 - $1.27 Million
265,370 Added 11.56%
2,561,796 $12.3 Million
Q4 2022

Feb 14, 2023

BUY
$1.22 - $2.85 $2.8 Million - $6.54 Million
2,296,426 New
2,296,426 $6.55 Million
Q3 2021

Nov 15, 2021

SELL
$1.27 - $8.17 $3.03 Million - $19.5 Million
-2,385,162 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$6.55 - $8.98 $550,730 - $755,047
-84,081 Reduced 3.41%
2,385,162 $18.1 Million
Q1 2021

May 17, 2021

SELL
$6.1 - $7.69 $187,099 - $235,867
-30,672 Reduced 1.23%
2,469,243 $16.3 Million
Q4 2020

Feb 16, 2021

BUY
$5.05 - $7.1 $12.6 Million - $17.7 Million
2,499,915 New
2,499,915 $16.2 Million

Others Institutions Holding ARDX

About ARDELYX, INC.


  • Ticker ARDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 154,636,000
  • Market Cap $1.15B
  • Description
  • Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...
More about ARDX
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.